Tommaso Tabaglio is a Senior Scientist at the A*STAR Institute of Molecular and Cell Biology and the co-founder of ImmuNOA Pte. Ltd, an A*STAR spinoff developing next-generation cell immunotherapies that was acquired by LionTCR in 2024. Tabaglio specialises in molecular biology, RNA splicing modulation and cancer research. He holds a BS in Medical Biotechnology from the University of Padua, Italy; an MS from the University of Milan, Italy; and a PhD in Biochemistry from the National University of Singapore. His research focuses on innovative approaches to modulate RNA splicing—spanning applications in cancer, cancer immunotherapy and genetic diseases.
